leadf
logo-loader
viewMydecine Innovations Group Inc
(
OTC:MYCOFFRA:0NFANEO:MYCO
)

Proactive Analyst Ed Stacey looks at Mydecine Innovations

Insight from Proactive analyst Ed Stacey on Mydecine Innovations Group, a biotech and life sciences company which is developing new therapies derived from psychedelics including psilocybin from mushrooms.

Read Ed Stacey's latest update

Quick facts: Mydecine Innovations Group Inc

Follow
OTC:MYCOF

Price: 0.303 USD

Market Cap: $72.32 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash...

FOR OUR FULL DISCLAIMER CLICK HERE

Mydecine Innovations Group™️ (NEO: MYCO) (OTC:MYCOF) (FSE:0NFA) Proactive...

Mydecine Innovations Group™️ (NEO: MYCO) (OTC:MYCOF) (FSE:0NFA) Proactive One2One Virtual Forum - 15th July 2021 Mydecine Innovations Group™️ (NEO: MYCO) (OTC:MYCOF) (FSE:0NFA) is an emerging biotech and life sciences company dedicated to developing and commercializing innovative solutions...

on 16/7/21

2 min read